Trial Profile
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2016
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Biomarker; Therapeutic Use
- 04 Feb 2016 New trial record